Role of phalatrikadi ghana in Fatty Liver

Comprehensive (Pharmaceutical, Analytical and Clinical) Study of Phalatrikadi Ghan in the management of Non-Alcoholic Fatty Liver Disease (NAFLD) - NILL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/059886

Enrollment

Registered

2023-11-15

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: • Patient of either sex, between the age group of 20 to 60 yrs, Sonologically diagnosed cases of fatty liver. • Fatty liver of grade I, II, III will be enrolled for clinical trial. • Patients having any of the components of metabolic syndrome, i.e., obesity, hypertension, diabetes mellitus, hypertriglyceridemia. • BMI >25, presenting with the symptoms of indigestion, abdominal discomfort, flatulence, etc.

Exclusion criteria

Exclusion criteria: Alcoholic stetohepatitis, Hepatitis B and C, cirrhosis of liver, jaundice, pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Relief in pain in abdomen anorexia loss of appetite flatulenceTimepoint: 90 days study with follow up after every 15 days	—

Secondary

Measure	Time frame
relief in sign & symptom like pain in abdomen anorexia loss of appetiteTimepoint: 90 days study with follow up after every 15 days	—

Countries

India

Contacts

Public ContactProf Anand Kumar Chaudhrary

Institute of medical science

pk197999@gmail.com9695156729

Outcome results